Palvella Therapeutics, Inc.
PVLA
$50.13
-$3.29-6.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.13M | 3.80M | 1.82M | 1.88M | 1.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.25M | 7.87M | 4.37M | 5.06M | 2.91M |
| Operating Income | -9.25M | -7.87M | -4.37M | -5.06M | -2.91M |
| Income Before Tax | -9.47M | -8.19M | -3.95M | -6.78M | -4.17M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.47M | -8.19M | -3.95M | -6.78M | -4.17M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.47M | -8.19M | -3.95M | -6.78M | -4.17M |
| EBIT | -9.25M | -7.87M | -4.37M | -5.06M | -2.91M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.86 | -0.74 | -0.31 | -1.22 | -2.47 |
| Normalized Basic EPS | -0.54 | -0.46 | -0.32 | -0.68 | -1.47 |
| EPS Diluted | -0.86 | -0.74 | -0.31 | -1.22 | -2.47 |
| Normalized Diluted EPS | -0.54 | -0.46 | -0.32 | -0.68 | -1.47 |
| Average Basic Shares Outstanding | 11.05M | 11.01M | 11.01M | 5.72M | 1.77M |
| Average Diluted Shares Outstanding | 11.05M | 11.01M | 11.01M | 5.72M | 1.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |